Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ 18 years of age.~* Rheumatoid arthritis of \> 6 months duration.~* Intolerant of methotrexate or continued treatment with methotrexate is considered inappropriate.~* All disease-modifying anti-rheumatic drugs (DMARD) are to be withdrawn prior to receiving study drug.~* Weight ≤ 150 kg.~Exclusion Criteria:~* Major surgery (including joint surgery) within 12 weeks prior to baseline or planned major surgery within 6 months after baseline.~* History of or current inflammatory joint disease other than rheumatoid arthritis (RA).~* Treatment with a biologic agent at any time prior to baseline.~* Intra-articular or parenteral corticosteroids ≤ 4 weeks prior to baseline.~* Active current infection or history of recurrent bacterial, viral, fungal or mycobacterial infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 8 mg/kg (Type: EXPERIMENTAL): Patients received 6 infusions of tocilizumab 8 mg/kg intravenously every 4 weeks and 12 injections of placebo to adalimumab subcutaneously every 2 weeks.
- Adalimumab 40 mg (Type: ACTIVE_COMPARATOR): Patients received 12 injections of adalimumab 40 mg subcutaneously every 2 weeks and 6 infusions of placebo to tocilizumab intravenously every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).